Managed Care

Apremilast in DMARD-Naïve Patients With Psoriatis Arthritis: PALACE 4 (Phase 3)

Alvin Wells, MD, PhD, of the Rheumatology and Immunotherapy Center in Oak Creek, Wisconsin, says that apremilast, which modulates intracellular inflammatory mediators, produced clinicallly significant improvements in signs and symptoms in treated patients in this 52-week study.


Medical Devices Summit Boston, MA February 19–20, 2015
3rd Annual Summit to Improve Adherence and Enhance Patient Engagement Philadelphia, PA March 9–10, 2015
Value-Added Solutions for Enhanced Customer Experience Philadelphia, PA March 9, 2015